Raymond James Believes Arcturus Therapeutics (ARCT) Won’t Stop Here
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Arcturus Therapeutics (ARCT), with a price target of $79.00. The company’s shares closed last Monday at $58.91, close to its 52-week high of $63.45.
According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 20.5% and a 44.0% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Galmed Pharmaceuticals, and NGM Biopharmaceuticals.
Arcturus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $64.00, implying a 9.1% upside from current levels. In a report issued on July 30, Roth Capital also initiated coverage with a Buy rating on the stock with a $77.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $63.45 and a one-year low of $8.51. Currently, Arcturus Therapeutics has an average volume of 850.1K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.